Inactive Instrument

Highlights Neurokine Pharmaceuticals Inc Other OTC

Equities

CAC611561100

End-of-day quote Other OTC Other stock markets
- ^USD	-

Apr. 03	BetterLife Pharma Inc. announced that it has received CAD 1.168 million in funding	CI
Mar. 04	BetterLife Pharma Inc. announced that it expects to receive CAD 0.1 million in funding	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BetterLife Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2023	Dec. 29	CI
Us Patent and Trademark Office Publishes Betterlife?S Comprehensive Patent for Betr-001 and Other Lsd Derivatives	Nov. 30	CI
BetterLife Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2023	23-09-27	CI
BetterLife Pharma Inc. Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001	23-09-12	CI
BetterLife Pharma Inc. Reports Earnings Results for the First Quarter Ended April 30, 2023	23-06-28	CI
BetterLife Pharma Inc. Fast Tracking Its US Patent for BETR-001 and Other LSD Derivatives	23-06-27	CI
BetterLife Pharma Inc. Continues Progress on BETR-001 IND-Enabling Studies	23-06-08	CI
BetterLife Pharma Inc. Reports Earnings Results for the Full Year Ended January 31, 2023	23-05-31	CI
BetterLife Pharma Inc. to Present BETR-001 Preclinical Data At the 2023 Annual Meeting of the Society of Biological Psychiatry in San Diego, California	23-04-25	CI
BetterLife Pharma Inc. Publishes Promising Results from Study Titled "A Non-Hallucinogenic LSD Analog with Therapeutic Potential for Mood Disorders	23-03-09	CI
BetterLife Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2022	22-12-22	CI
BetterLife Pharma Present BETR-001 Preclinical Data at Annual Meeting of American College of Neuropsychopharmacology	22-12-02	MT
BetterLife To Present BETR-001 Preclinical Data at the 61ST Annual Meeting of the American College of Neuropsychopharmacology in Phoenix, Arizona	22-12-02	CI
BetterLife Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2022	22-09-27	CI
BetterLife Pharma Inc. Files Comprehensive Patent for BETR-001 and Other LSD Derivatives	22-09-27	CI
BetterLife Pharma Inc. Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical Depression Studies	22-07-06	CI
BetterLife Pharma Inc. Reports Earnings Results for the First Quarter Ended April 30, 2022	22-06-28	CI
BetterLife Pharma Inc. Reports Earnings Results for the Full Year Ended January 31, 2022	22-05-31	CI
BetterLife Pharma Inc. Obtains Additional Positive Data Confirming the Anti-Depressant Activity of Its Lead Compound 2-bromo-LSD (BETR-001) in Preclinical Models of Depression	22-04-06	CI
BetterLife Pharma Inc. Obtains in Vivo PK Data for BETR-001 Confirming Its Bioavailability in Brain	22-03-16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Neurokine Pharmaceuticals Inc Other OTC

Equities

CAC611561100

Highlights

Filters